Serial Bronchoalveolar Lavage Fluid Aspergillus Galactomannan and Treatment Response in Invasive Pulmonary Aspergillosis

Daniel Z P Friedman; Elitza S Theel; Randall C Walker; Holenarasipur R Vikram; Raymund R Razonable; Paschalis Vergidis

doi:10.1093/ofid/ofae114

Serial Bronchoalveolar Lavage Fluid Aspergillus Galactomannan and Treatment Response in Invasive Pulmonary Aspergillosis

Open Forum Infect Dis. 2024 Mar 1;11(4):ofae114. doi: 10.1093/ofid/ofae114. eCollection 2024 Apr.

Authors

Daniel Z P Friedman^{1

2}, Elitza S Theel³, Randall C Walker¹, Holenarasipur R Vikram⁴, Raymund R Razonable^{1

5}, Paschalis Vergidis^{1

5}

Affiliations

¹ Section of Infectious Disease, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
² Section of Infectious Diseases and Public Health, University of Chicago, Chicago, Illinois, USA.
³ Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
⁴ Division of Infectious Diseases, Mayo Clinic, Phoenix, Arizona, USA.
⁵ William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA.

Abstract

We studied patients diagnosed with aspergillosis based on positive bronchoalveolar lavage (BAL) Aspergillus galactomannan (GM) who had follow-up BAL sampling within 180 days. GM trend and clinical outcome were concordant in only 60% (30/50). While useful for the initial diagnosis, BAL GM trending does not always correlate with treatment response.

Keywords: aspergillosis; bronchoscopy; galactomannan; hematopoietic stem cell transplant; solid organ transplant.